awmsg logo



sildenafil citrate (Revatio®)


Reference No. 667

Publication date:
03/02/2011


Appraisal information

sildenafil citrate (Revatio®) 0.8 mg/ml solution for injection


Company: Pfizer Ltd
BNF category: Cardiovascular system
NMG meeting date: 17/11/2010
AWMSG meeting date: 15/12/2010
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1910
Ministerial ratification: 27/01/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Sildenafil citrate (Revatio®) solution for injection is recommended within its current licensed indication as an option for use within NHS Wales for the treatment of patients with pulmonary arterial hypertension (PAH) who are currently prescribed oral sildenafil citrate and who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable. AWMSG recommends that its use be restricted to a physician experienced in the treatment of PAH. Sildenafil citrate (Revatio®) solution for injection is not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download